Midsize drugmakers have made more deals than large drugmakers this year

Midsize drugmakers have made the most acquisitions and mergers this year, replacing the larger drugmakers that typically make the most deals by value, The Wall Street Journal reported July 5.

So far, midsize drugmakers have made nine deals valued at a total of $13.1 million, twice what large drugmakers have spent on eight acquisitions during the same time period, according to Evaluate Group, a pharmaceutical data provider.